Cargando…
Irradiation stent with (125)I plus TACE versus sorafenib plus TACE for hepatocellular carcinoma with major portal vein tumor thrombosis: a multicenter randomized trial
Treatment strategy for hepatocellular carcinoma (HCC) and Vp4 [main trunk] portal vein tumor thrombosis (PVTT) remains limited due to posttreatment liver failure. We aimed to assess the efficacy of irradiation stent placement with (125)I plus transcatheter arterial chemoembolization (TACE) (ISP-TACE...
Autores principales: | Lu, Jian, Guo, Jin-He, Ji, Jian-Song, Li, Yu-Liang, Lv, Wei-Fu, Zhu, Hai-Dong, Sun, Jun-Hui, Ren, Wei-Xin, Zhang, Fu-Jun, Wang, Wei-Dong, Shao, Hai-Bo, Cao, Guang-Shao, Li, Hai-Liang, Gao, Kun, Yang, Po, Yin, Guo-Wen, Zhu, Guang-Yu, Wu, Fa-Zong, Wang, Wu-Jie, Lu, Dong, Chen, Sheng-Qun, Min, Jie, Zhao, Yang, Li, Rui, Lu, Li-Gong, Lau, Wan Yee, Teng, Gao-Jun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10389427/ https://www.ncbi.nlm.nih.gov/pubmed/37038986 http://dx.doi.org/10.1097/JS9.0000000000000295 |
Ejemplares similares
-
Comparing the effectiveness and safety of Sorafenib plus TACE with Apatinib plus TACE for treating patients with unresectable hepatocellular carcinoma: a multicentre propensity score matching study
por: Yin, Liang, et al.
Publicado: (2023) -
Prospective study of TACE combined with sorafenib vs TACE combined with (125)I seed implantation in the treatment of hepatocellular carcinoma with portal vein tumor thrombus and arterioportal fistulas
por: Zhao, Xiao-Hui, et al.
Publicado: (2022) -
TACE Plus Lenvatinib Versus TACE Plus Sorafenib for Unresectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Prospective Cohort Study
por: Yang, Biao, et al.
Publicado: (2021) -
Real-world efficacy and safety of TACE plus camrelizumab and apatinib in patients with HCC (CHANCE2211): a propensity score matching study
por: Jin, Zhi-Cheng, et al.
Publicado: (2023) -
Changing TACTICS in intermediate HCC: TACE plus sorafenib
por: Radu, Pompilia, et al.
Publicado: (2020)